NasdaqCM:AKBABiotechs
Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts
Akebia Therapeutics just took a 26% hit, with the stock sliding to about US$0.95, as investors reacted to a quarter that put its valuation strain back in the spotlight. The immediate trigger was Q2 revenue of US$49.1 million and another quarterly net loss. The key issue is what that means for a stock that trades on a very low price to sales ratio and a large gap to modelled future cash flow value.
The short term looks painful on the screen. The bigger question is how long Akebia can run its...